ArticleBMC cancer2026
Development and internal validation of the CLIP-M score for advanced mucosal malignant melanoma: exploratory prognostic stratification and comparative assessment with the RMH score.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucosal malignant melanoma (MMM) is a rare, aggressive malignancy with poor prognosis in the advanced setting. Although the Royal Marsden Hospital (RMH) score is widely used in advanced malignancies, its utility in advanced MMM remains insufficiently characterized. We aimed to develop a composite prognostic score and compare its performance with RMH.
methodsWe analyzed 80 patients with advanced MMM (metastatic or unresectable) from a multicenter database. Pretreatment inflammatory indices and clinical variables were evaluated. The CLIP-M score (Clinical and Inflammatory Prognostic Score in Mucosal Melanoma) was derived from independent predictors in multivariable Cox regression and internally validated by bootstrap resampling. Predictive accuracy was compared with RMH using time-dependent AUCs, Harrell's C-index, and Kaplan-Meier estimates.
resultsDuring a median follow-up of 65.2 months, 63 deaths occurred. SII was selected as the biological component. CLIP-M integrated high SII (≥ 789; derived by 12-month time-dependent ROC analysis), age ≥ 65 years, and non-head & neck primary location. Time-dependent AUCs numerically favored CLIP-M over RMH at 12 months (0.731 vs. 0.613), 24 months (0.824 vs. 0.680), and 36 months (0.863 vs. 0.697), with a nominal 36-month between-model difference that did not remain significant after correction for three time horizons (ΔAUC = 0.166; nominal p = 0.039). Bootstrap internal validation showed moderate discrimination, with apparent and optimism-corrected C-indices of 0.648, and acceptable 12-month calibration. CLIP-M stratified patients into low-risk (score 0-1) and high-risk (score 2-3) groups with divergent median overall survival (24.8 vs. 6.4 months; HR 4.03, 95% CI 2.25-7.22; p < 0.001).
conclusionCLIP-M provided exploratory, clinically interpretable risk stratification in advanced MMM and showed numerically higher discrimination than RMH; however, optimism-corrected performance was moderate and external validation is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.